Invention Grant
- Patent Title: Tumor specific T-cell receptors
-
Application No.: US14648314Application Date: 2013-11-29
-
Publication No.: US10683336B2Publication Date: 2020-06-16
- Inventor: Thomas Blankenstein , Gerald Willimsky
- Applicant: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) BERLIN-BUCH
- Applicant Address: DE Berlin
- Assignee: Max-Delbrüeck-Centrum Für Molekulare Medizin (MDC) Berlin-Buch
- Current Assignee: Max-Delbrüeck-Centrum Für Molekulare Medizin (MDC) Berlin-Buch
- Current Assignee Address: DE Berlin
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@10ccf3a4
- International Application: PCT/EP2013/075141 WO 20131129
- International Announcement: WO2014/083173 WO 20140605
- Main IPC: C07K14/725
- IPC: C07K14/725 ; C07K14/47 ; A61K39/00 ; A61K38/00
Abstract:
The present invention relates to a method for the production of novel T-cell receptors (TCR) which provide a reduced risk of adverse events in immune therapy, specifically in adoptive T cell transfer. The TCRs produced according to the method of the invention are specific for tumor cells and do not react with healthy tissue. Furthermore provided are nucleic acids encoding the TCR of the invention, vectors and host cells comprising the TCRs of the invention as well as their use is the treatment of tumorous diseases.
Public/Granted literature
- US20150307585A1 TUMOR SPECIFIC T-CELL RECEPTORS Public/Granted day:2015-10-29
Information query
